JAMIE BOUCHARD: Open Payments
NPI 1740661917 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$770 in 39 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $939 · 2025 $770
Food & beverage: $619Education: $151
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $169 |
| Teva Pharmaceuticals USA, Inc. | 3 | $147 |
| Alkermes, Inc. | 12 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Tempus AI, Inc | 2 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
Products named: VRAYLAR, ARISTADA, CAPLYTA, LYBALVI, TEMPUS PIXEL, INGREZZA, AUSTEDO XR, Jornay PM.
Industry payments across TX — which companies pay providers there.
